Clinical Study

First In Human Study Of Broadly Neutralizing Antibodies To Control Hiv

Posted Date: Jun 11, 2019

  • Investigator: Carl Fichtenbaum
  • Specialties:
  • Type of Study: Drug

A5377 is a phase I, first-in-human, ascending dose study of SAR441236. It will include two arms with four cohorts in each. A ninth cohort may be enrolled. The DURATION is 24 or 72 weeks: Participants will be on study for 24 weeks, with the exception of participants in Cohort 4 who will be on study for 72 weeks. The number of persons to enroll will be between 54-60 evaluable participants: 6 participants each in Cohorts 1-3 and 5-8, and 12 in Cohort 4. If warranted, a ninth cohort of six participants may be enrolled. In Arm A: Adults with HIV-1, 18 to 70 years of age on suppressive combination antiretroviral therapy (ART) with plasma HIV-1 RNA levels =50 copies/mL for at least 12 months and CD4 count of =200 cells/mm3. Arm B: Treatment-naïve adults with HIV-1, 18 to 70 years of age with plasma HIV-1 RNA >5000 copies/mL and <100,000 copies/mL and CD4 count of =350 cells/mm3 who intend to initiate combination ART.


Hiv Infection With Undetectable Hiv Level And Cd4 T-Cell Count > 200 On Treatment Or >350 Who Intend To Start Treatment


Hiv, Broadly Neutralizing Antibodies

For More Information:

Sharon Kohrs

  • This contact page is monitored Monday – Friday during business hours, 8 am to 5 pm EST. Do not rely on communication through this website for medical treatment or care. This website is not designed for such purposes.
    For questions regarding clinical studies at UC Health, contact us at or (513) 245-3417.